Wire flash
CR Double-Crane's Propranolol Hydrochloride Injection Passes Consistency Evaluation
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 23, China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, China Resources Zizhu Pharmaceutical, has received a Drug Supplement Application Approval Notice from the National Medical Products Administration (NMPA) for Propranolol Hydrochloride Injection. The approval adds a new specification of 2ml:2mg, and the drug has passed the generic drug quality and efficacy consistency evaluation. The drug is indicated for controlling supraventricular tachyarrhythmias and exertional angina pectoris. As of the announcement date, the company had invested a total of 3.3384 million yuan in research and development for this product. In 2025, the drug generated sales revenue of 3.0622 million yuan.
Source report
Beijing, September 23 — China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, China Resources Zizhu Pharmaceutical, has received the Drug Supplement Application Approval Notice issued by the National Medical Products Administration (NMPA) for Propranolol Hydrochloride Injection.
The approval authorizes the addition of a new specification: 2ml:2mg. The drug has passed the consistency evaluation for generic drug quality and efficacy.
Indications
The product is indicated for the management of:
- Supraventricular tachyarrhythmias
- Effort angina pectoris
R&D and Sales Data
- Total cumulative R&D investment by the company as of the announcement date: RMB 3.3384 million
- Sales revenue of the drug in 2025: RMB 3.0622 million
Source
财联社Eastern
Part of this Story
China Resources Double-Crane’s Propranolol Injection Passes Generic Consistency Evaluation in China